Rochelle Castillo is a Dermatology physician affiliated with Brigham and Women's Hospital. OpenAlex indexes 49 publications with 1,433 citations (h-index 14); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
221 Longwood Ave
Boston, MA 021155804
Telephone
617-732-4918Provider last certified this registry record 20 May 2025.
Clinical trials
- Oral Zinc Gluconate as Treatment for Recalcitrant Cutaneous Warts: A Randomized, Double-blind, Placebo-controlled Trial
Sponsor: Philippine Dermatological Society
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20254 payments
- AstraZeneca UK LimitedProgram year20252 payments
- ABBVIE INC.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
39.6%Corticosteroid39.6%Clobetasol Propionate100%Part D<11 patientsCancer & immunology
33.3%Interleukin-17A Antagonist33.3%Taltz Autoinjector100%Part D<11 patientsDermatology
27.1%Interleukin-4 Receptor alpha Antagonist27.1%Dupixent Pen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Anifrolumab use in pregnancy: maternal and neonatal outcomes in patients with systemic lupus erythematosus
EULAR Rheumatology Open
2026 - Improvement in dermatomyositis-associated muscle disease with anifrolumab
British Journal of Dermatology
2025 - Inpatient Management of Connective Tissue Disease-Related Digital Ischemia
Current Dermatology Reports
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Ridker, MD
Brigham and Women's Hospital
Scott Solomon, MD
Brigham and Women's Hospital
Dennis Selkoe, MD
Brigham and Women's Hospital
Marc Pfeffer, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”